U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 52

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated January 27, 2011,
1. Bayhealth Medical Center	3. License number 07-14850-01 is amended in its entirety to read as follows:
2. 640 South State Street Dover, Delaware 19901	4. Expiration date May 31, 2014
	5. Docket No. 030-07565 Reference No. 07-27897-01/030-29521

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1.7 curies
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed Sources (Mills Biopharmaceuticals Model I-125SL; Bard Brachytherapy, Inc. Model STM 1251; Best Medical International Model 2300 Series and 81-01; Amersham Corporation Model CDCT1; and Theragenics TheraSeed Model 200)	D. 6.7 curies
E. Any byproduct material permitted by 10 CFR 35.500	E. Sealed Sources (Isotope Products Laboratory Model 301B or DuPont Merck Model NES-8424)	E. 323 millicuries per source and 700 millicuries total
F. Yttrium 90	F. Any	F. 110 millicuries
G. Radium 226	G. Sealed Sources (manufacturer unknown)	G. 15.7 microcuries

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
07-14850-01

Docket or Reference Number
030-07565

Amendment No. 52

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
E. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).
F. Calibrations and checking of licensee's instruments.
G. Storage only, pending disposal.

CONDITIONS

10. A. Licensed material may be used or stored only at the licensee's facilities located at Bayhealth Medical Center – Kent General Hospital, 640 South State Street, Dover, Delaware and Bayhealth Medical Center – Milford Memorial Hospital, 21 West Clarke Avenue, Milford, Delaware.

B. Licensed material in Item 6.B. may also be used or stored at 1100 Forrest Avenue, Dover, Delaware and 802 North DuPont Highway, Milford, Delaware.

C. Licensed material in Item 6.C., for which the patient can be released in accordance with the provisions in 10 CFR 35.75, may also be used or stored at Cancer Care Center located at 793 South Queen Street, Dover, Delaware.

D. Licensed material in Item 6.G. will be stored at 21 West Clarke Avenue, Milford, Delaware.

11. The Radiation Safety Officer for this license is Martin Begley, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Victoria Kong, M.D.	35.100; 35.200; Oral administration of sodium iodide Iodine-131 for diagnostic studies; 35.500
Martin Begley, M.D.	35.100; 35.200; Oral administration of sodium iodide Iodine-131 for diagnostic studies

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
07-14850-01

Docket or Reference Number
030-07565

Amendment No. 52

Authorized Users	Material and Use
Raphael Caccese, M.D.	35.100; 35.200; Oral administration of sodium iodide Iodine-131 for diagnostic studies
Thomas Vaughn, M.D.	35.100; 35.200; Oral administration of sodium iodide Iodine-131 for diagnostic studies
Michael Polise, D.O.	35.100; 35.200; Oral administration of sodium iodide Iodine-131 for diagnostic studies
Ravi Kasit, M.D.	35.100; 35.200; Oral administration of sodium iodide Iodine-131 for diagnostic studies
Michael Amygdalos, M.D.	35.100; 35.200; Oral administration of sodium iodide Iodine-131 for diagnostic studies
John Lahaniatis, M.D.	35.300; 35.400
Jeffrey Jackerson, D.O.	35.100; 35.200
Kathleen M. Hughes, M.D.	35.100; 35.200
Amit Newatia, M.D.	35.100; 35.200
Yogi Trivedi, M.D.	35.100; 35.200
Vijay Viswanathan, M.D.	35.100; 35.200
David Ramos, M.D.	35.200
Pedro Perez, M.D.	35.200

C. The following individuals are authorized users for non-medical uses as indicated:

Users	Material and Use
John Lahaniatis, M.D.	Yttrium 90 for instrument calibration
Martin Begley, M.D.	Radium 226 check source in storage

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
07-14850-01

Docket or Reference Number
030-07565

Amendment No. 52

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A.	Letter dated May 23, 2004	[ML031630790]
B.	Application dated February 24, 2004	[ML040700204]
C.	Letter dated May 14, 2004	[ML041480428]
D.	Letter dated January 27, 2011	[ML110320227]
E.	Letter dated February 23, 2011	[ML110550086]

For the U.S. Nuclear Regulatory Commission

Date February 25, 2011

By ***Original signed by Tara L. Weidner***

Tara L. Weidner
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406